药明康德2025年第一季度业绩亮眼，营业收入达96.55亿元，同比增长20.96%，净利润36.72亿元，同比大幅增长89.06%。受此利好消息影响，港股市场CRO板块集体走强，其中凯莱英涨近7%，药明康德涨近6%，维亚生物涨超3%，康龙化成和昭衍新药涨超2%。这一强劲表现不仅提振了投资者信心，也反映了市场对CRO行业前景的乐观预期。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.